Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Nkarta Inc
(NQ:
NKTX
)
6.410
+0.060 (+0.94%)
Streaming Delayed Price
Updated: 1:36 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Nkarta Inc
< Previous
1
2
3
4
Next >
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2022
December 22, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 08, 2022
During Thursday's trading, 138 companies set new 52-week lows.
Via
Benzinga
SVB Leerink Picks This Well-Positioned NK Cell-Focused Stock, Sees 117% Upside
July 18, 2022
Via
Benzinga
Expert Ratings for Nkarta
April 26, 2022
Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter:
Via
Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
VF Corp, Verve Therapeutics And Some Other Big Stocks Moving Lower On Monday
December 05, 2022
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Why Nkarta Stock (NKTX) Is Volatile During Monday's Session?
December 05, 2022
Nkarta Inc (NASDAQ: NKTX) shares are trading lower by 5.82% to $8.09, reversing after trading higher during the pre-market session, after the company announced updated data from its Phase 1 dose...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 05, 2022
The biggest pre-market stock movers for Monday include many Chinese shares that traders will want to keep an eye on today!
Via
InvestorPlace
Investors Cheer Nkarta's First NK Cell Data With Multiple Complete Responses
April 25, 2022
Via
Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
October 25, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
Benzinga
7 Unknown Biotech Stocks That Could Rocket in 2023
September 23, 2022
Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.
Via
InvestorPlace
Cowen Slashes Price Target On This Stock By Over 78%; Also Check Out Some Other Big PT Changes
August 12, 2022
Cowen & Co. cut the price target for The RealReal, Inc. (NASDAQ: REAL) from $14 to $3. RealReal shares fell 0.7% to $3.1388 in pre-market trading.
Via
Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
June 14, 2022
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
July 28, 2022
Via
Benzinga
Positive Clinical Results Put Nkarta Stock on the Fast Track
May 09, 2022
NKTX stock is a fast mover, and a recent share-price bump came in the wake of exciting data from a "killer cell" anti-cancer research program.
Via
InvestorPlace
Executives Buy More Than $32M Of 3 Stocks
May 02, 2022
Although US stocks closed sharply lower on Friday, there were a few notable insider trades.
Via
Benzinga
How Is The Market Feeling About Nkarta Inc. - Common Stock?
April 27, 2022
Nkarta Inc. - Common Stock's (NASDAQ:NKTX) short percent of float has risen 8.05% since its last report. The company recently reported that it has 1.84 million shares sold short,...
Via
Benzinga
71 Biggest Movers From Yesterday
April 27, 2022
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...
Via
Benzinga
34 Stocks Moving In Tuesday's Mid-Day Session
April 26, 2022
Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday...
Via
Benzinga
Futures Slide Ahead Of Tech Earnings Deluge
April 26, 2022
Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices.
Via
Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 26, 2022
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
April 26, 2022
HC Wainwright & Co. raised Nkarta, Inc. (NASDAQ: NKTX) price target from $25 to $36. Nkarta shares fell 7.2% to $17.38 in pre-market trading.
Via
Benzinga
Mid-Afternoon Market Update: Nasdaq Rises 70 Points; Eliem Therapeutics Shares Slide
April 25, 2022
U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite gaining around 70 points on Monday.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 25, 2022
Via
Benzinga
60 Biggest Movers From Yesterday
April 26, 2022
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares climbed 140.9% to close at $18.72 on Monday after the company announced Phase 1 data from independent dose finding studies of its two...
Via
Benzinga
Mid-Day Market Update: Crude Oil Tumbles Over 6%; Nkarta Shares Spike Higher
April 25, 2022
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 400 points on Monday.
Via
Benzinga
34 Stocks Moving In Monday's Mid-Day Session
April 25, 2022
Gainers Nkarta, Inc. (NASDAQ: NKTX) shares jumped 108.6% to $16.21 after the company announced Phase 1 data from independent dose finding studies of its two lead chimeric antigen...
Via
Benzinga
Why Is Nkarta (NKTX) Stock Soaring 90% Today?
April 25, 2022
Nkarta (NKTX) stock is rocketing higher on Monday after the company released preliminary data from a Phase 1 clinical trial.
Via
InvestorPlace
Mid-Morning Market Update: Markets Open Lower; Dow Tumbles Over 300 Points
April 25, 2022
U.S. stocks opened lower this morning, with the Dow Jones dropping more than 300 points on Monday.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.